Biofrontera reports record $12 million net product revenue in Q2 2026, marking its strongest first-half performance as a U.S. standalone business.
Biofrontera announced a September 28, 2026 PDUFA date for its pending application, with plans to launch its superficial basal cell carcinoma treatment in Q1 2027. The company is addressing ITC lamp remediation requirements to support the rollout.
The company reported $12 million in net product revenue for Q2 2026, calling it the strongest operating quarter in its history as a U.S. standalone business. The first half of 2026 also marked the strongest H1 performance, driven by product demand.
Management highlighted operational momentum but did not disclose immediate market reactions to the financial or regulatory updates.